Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer-Reference-Cited by-同舟云学术

Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer

Published:2021-02-04 Issue:3 Volume:186 Page:753-760
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

da Silva Leonardo Roberto,de Andrade Camila Annicchino,Brenelli Fabrício,Ramalho Susana,Reinert Tomás,de Souza Alessandra Borba Anton,da Silva Ana Elisa Ribeiro,de Paula Leite Kraft Maria Beatriz,de Vasconcelos Vivian Castro Antunes,Frasson Antônio Luiz,Torresan Renato Zochio,Cabello Cesar,Ellis Matthew J.,Zeferino Luiz Carlos^ORCID

Funder

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-020-06076-5.pdf

Reference37 articles.

1. Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Brit J Cancer 103(6):759–764

2. Reinert T, Ramalho S, Gonçalves R, Barrios CH, Graudenz MS, Bines J (2016) Multidisciplinary approach to neoadjuvant endocrine therapy in breast cancer: a comprehensive review. Rev Bras Ginecol Obstet Rev Bras Soc Ginecol Obstet 38(12):615–622

3. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11):1527–1532